Merck KGaA's pimicotinib met its primary endpoint in Phase 3 MANEUVER trial for tenosynovial giant cell tumors, showing 54% ...
Novartis will pay $150 million upfront to Schrödinger, in a pact announced Tuesday to work together on several ...
Diverge, a startup helping Medicaid members access care, raised $52 million led by Alphabet's GV. The company, launched in ...
AstraZeneca announces $2 billion investment to create 1,000 new US jobs, adding to previous $1.5 billion commitment. The $3.5 ...
AstraZeneca and Daiichi Sankyo withdrew their filing for datopotamab deruxtecan (Dato-DXd) in nonsquamous non-small cell lung ...
A flashy collaboration between Sanofi, OpenAI and Formation Bio produced its first AI-powered tool, aiming to speed up the ...
GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...
Apollo Therapeutics will pay $12M upfront and up to $926M in milestone payments to Sunshine Lake Pharma for worldwide rights (excluding China) to their FGF21/GLP-1 dual receptor agonist ...
Trace Neuroscience, a startup spun out of Maze Therapeutics’ pipeline, broke cover Tuesday morning with $101 ...
Roche is aligning with Flare Therapeutics to work on small molecules for cancer by going after transcription factor targets, ...
Bayer reiterated its plans to ride out the generic-driven sales decline of its thrombosis drug Xarelto, as the ...
Me is closing its therapeutics division and will wind down ongoing clinical trials, the struggling genetic testing company ...